

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/030,262	CRIERE ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Lakshmi S. Channavajjala	1615	

**All Participants:**

**Status of Application:** non-final

(1) Lakshmi S. Channavajjala.

(3) \_\_\_\_\_.

(2) Brian O'Shaughnessy.

(4) \_\_\_\_\_.

**Date of Interview:** 27 June 2006

**Time:** \_\_\_\_\_

**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☐ No  
 If Yes, provide a brief description:

**Part I.**

Rejection(s) discussed:

Claims discussed:

Prior art documents discussed:


**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

*See Continuation Sheet*

**Part III.**

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

  
 (Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Examiner informed attorney that the supplemental response filed on 6-23-06, in response to the telephonic interview (dated 6-23-06) has been entered. It was informed to the attorney that the supporting evidence from Merck Index, showing the correlation between generic names (of Dimethicone and Simethicone, recited in claims 19 and 31) and their trade names (recited in the instant specification) is not persuasive because the evidence presented is from the 13th Edition of Merck Index, which is published after the effective filing date of the instant application. The attorney informed examiner that he did not have access to the earlier edition of Merck Index. Examiner verified the above information from the 12th edition of Merck Index (published 1996) and it was mutually agreed that a copy of the 12th Edition showing equivalency between the chemical names of Dimethicone and Simethicone will be attached to this interview summary.